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Abstract: Stroke is a severe neurological disorder in humans that results from an interruption of the
blood supply to the brain. Worldwide, stoke a↵ects over 100 million people each year and is the
second largest contributor to disability. Dyslipidemia is a modifiable risk factor for stroke that is
associated with an increased risk of the disease. Traditional and non-traditional lipid measures are
proposed as biomarkers for the better detection of subclinical disease. In the central nervous system,
lipids and lipid mediators are essential to sustain the normal brain tissue structure and function.
Pathways leading to post-stroke brain deterioration include the metabolism of polyunsaturated fatty
acids. A variety of lipid mediators are generated from fatty acids and these molecules may have
either neuroprotective or neurodegenerative e↵ects on the post-stroke brain tissue; therefore, they
largely contribute to the outcome and recovery from stroke. In this review, we provide an overview
of serum lipids associated with the risk of ischemic stroke. We also discuss the role of lipid mediators,
with particular emphasis on eicosanoids, in the pathology of ischemic stroke. Finally, we summarize
the latest research on potential targets in lipid metabolic pathways for ischemic stroke treatment and
on the development of new stroke risk biomarkers for use in clinical practice.
Keywords: eicosanoids; cholesterol; ischemic stroke; ischemia; lipoproteins; polyunsaturated
fatty acids
1. Introduction
Stroke is a severe neurological disorder in humans that results from an interruption of the blood
supply to the brain caused by a vascular occlusion (ischemic stroke, IS) or a blood vessel rupture
or leakage (hemorrhagic stroke, HS). Within seconds, the insu cient blood supply leads to a strong
oxygen-glucose deprivation (OGD) of the brain tissue, which initiates a cascade of pathophysiological
response consequently leading to neuronal death and severe neurological deterioration. According
to the Global Burden of Disease study, in 2017, stroke a↵ected 104.2 million people worldwide;
of them, 82.4 million were a↵ected by ischemic stroke. Stroke is the second largest contributor to
disability-adjusted life years in the world after ischemic heart disease, resulting in up to 50% of survivors
being chronically disabled, and is the second most common cause of death [1,2]. The age-standardized
global rate of new strokes reached 150.5 per 100,000 people in 2017 [3].
Primary and secondary prevention of stroke is crucial, considering that over 80% of the global
stroke burden is attributable to a few risk factors that can be improved significantly. Many risk factors
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for stroke have been documented, including hypertension, current smoking, diabetes, abdominal
obesity, poor diet, inactivity, excessive alcohol consumption, cardiac causes and stress/depression [4].
Dyslipidemia is a modifiable risk factor for stroke and is associated with a 1.8- to 2.6-times relative risk
of stroke.
In the central nervous system, lipids and lipid mediators are essential to sustain the normal
structure and function of brain tissue. Pathways leading to post-stroke brain deterioration include
the metabolism of polyunsaturated fatty acids (PUFAs). The rapid and extensive release of PUFAs
from cell membranes starts in the brain tissue immediately after the onset of ischemia. The lipids
released are utilized in either enzymatic or non-enzymatic reactions, generating diverse classes of
short-lived, lipid mediators, e.g., eicosanoids. These molecules have either neuroprotective or
neurodegenerative e↵ects on the post-stroke brain tissue; thus, they largely contribute to the outcome
and recovery from stroke. Because the brain infarct area consists of two zones—the ischemic core,
which is generally considered unsalvageable because of the greatest damage, and the surrounding
area called the penumbra, where the blood flow during stroke is only partially reduced—the brain
cells located in the penumbra may be rescued from degeneration by timely intervention. Numerous
PUFA-derived lipid mediators contribute to the brain injury occurring after the ischemic stroke.
In this review, we provide an overview of serum lipids associated with the risk of ischemic stroke.
We also discuss the role of lipid mediators, with particular emphasis on eicosanoids, in the pathology
of ischemic stroke. Finally, we summarize the latest research on potential targets in lipid metabolic
pathways for ischemic stroke treatment and on the development of new stroke risk biomarkers for use
in clinical practice.
2. Association of Serum Lipids with the Risk of Stroke
Dyslipidemia is conventionally considered to play an important role in the pathogenesis of stroke,
primarily ischemic stroke. Traditional lipid parameters, represented by increased concentrations of
total cholesterol (TC), triglycerides (TGs), low-density lipoprotein cholesterol (LDL-C), and decreased
high-density lipoprotein cholesterol (HDL-C), have been identified as risk factors and predictors of
cardiovascular disease, including stroke [5–7]. The assessment of lipid ratios such as TC/HDL-C,
TG/HDL-C, and LDL-C/HDL-C is recognized as a better predictor of vascular risk compared to
traditional lipid parameters [8]. In addition to standard lipid components testing, the analysis of
composition, particle size, and density of lipids and lipoproteins [e.g., lipoprotein(a), [Lp(a)]], have
been proposed as biomarkers for the better detection of subclinical diseases [9].
Lipid profile components and the risk of ischemic stroke are discussed in subsequent paragraphs
and summarized in Figure 1.
2.1. Cholesterol and the Risk of Stroke
As one modifiable risk factor, TC has been shown by many studies to be associated with the risk
of stroke [10]. Although the relationship between lipid levels and coronary heart disease (CHD) is well
established, the results of observational studies investigating the relationship between lipid profile
and stroke are less conclusive. Some data from Asian and American studies indicate that TC is not
identified as being associated or shows only weak relationships with various stroke subtypes [11,12].
Until the beginning of the 21st century, research on this topic yielded inconsistent results [13–15] and
led to conflicting views on the importance of circulating cholesterol in IS [5,16]. Part of the controversy
is related to the methodological shortcomings of previous studies. Many did not investigate the final
point of interest, namely the ischemic stroke incident, but focused rather on endpoints such as fatal
stroke or a combination of IS and HS, which are clearly di↵erent pathophysiological units. Some studies
lack data on cholesterol subfraction levels or rely on lipid profile measurements only after a stroke has
occurred. Additionally, few studies are large enough to examine the dose–response pattern in each sex
group, which is another important aspect of the nature of this disease [11].
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Figure 1. Lipid profile components and the risk of ischemic stroke. The reference values of the
specified parameters may vary slightly according to di↵erent diagnostic recommendations. The arrow
down indicates a low number of particles; the arrow up indicates a high number of particles.
NA—not analyzed.
In later years, a number of studies appeared that took into account the previous suggestions of
scientists. Some reports have shown a positive association between TC and IS [17], whereas an inverse
relationship between TC and HS was found in others [17,18]. In a meta-analysis, primarily in Europe
and North America, low-density lipoprotein cholesterol is associated with ischemic stroke but not with
hemorrhagic stroke [19]. In addition, elevated low-density lipoprotein cholesterol is shown to be one of
the most important risk factors for coronary artery disease and stroke, while high-density lipoprotein
cholesterol is protective [20–22]. A study by Tirschwell et al. shows that elevated cholesterol and
reduced HDL-C levels are associated with an increased risk of IS [6]. The e↵ect of hyperlipidemia may
be di↵erent depending on the ischemic stroke subtype. A significant and positive relationship was
found in the case of atherothrombotic infarction, but a negative association was observed in the case of
cardioembolic infarction [23].
Too low values of lipid components may also be responsible for an increased risk of stroke.
The risk of HS is higher when TC is lower than 120 mg/dL. LDL-C and TC seem to be associated with
hemorrhagic stroke. In contrast, the risk of ischemic and hemorrhagic stroke may be higher when
HDL-C is lower than 50 mg/dL [24].
2.2. Hypertriglyceridemia and Ischemic Stroke
Few reports to date have shown the role of triglycerides in acute stroke and recovery after stroke.
The studies that have evaluated this association report diverse associations [7,25,26]. According to a
study published in 2012 in the Stroke journal, the strongest predictor of stroke risk in women is TC, the
most-overlooked lipid in the cholesterol profile. The authors found that people with the highest TC
levels are 56% more likely to have ischemic stroke than those with the lowest levels [27]. Triglyceride
levels and their role in ischemic stroke have already been the subject of intensive research [28,29].
Large-scale epidemiological studies also detected a relationship between high non-fasting triglyceride
levels and the risk of ischemic stroke [30,31], while results in smaller cohorts remain inconclusive [29].
Weir et al. suggested the opposite results and showed that low TG level, not low TC concentration,
Int. J. Mol. Sci. 2020, 21, 3618 4 of 26
independently predicts poor outcome after acute stroke [32]. The mechanisms by which triglycerides
a↵ect ischemic stroke are still unexplained [33]. Triglyceride-rich lipoproteins and high TC levels can
have a direct atherogenic e↵ect and appear to be an indicator of atherosclerotic and prothrombotic
changes. Elevated TC levels are associated with abnormalities in the coagulation cascade and
fibrinolysis that is associated with ischemic stroke [34]. The e↵ects of triglycerides are likely to
be multifactorial.
2.3. Non-Traditional Lipid Profiles as Stroke Predictors
Human lipid profiles are currently actively studied, including not only traditional but
also non-traditional lipid profiles, primarily as independent predictors of cardiovascular disease
(CVD) [35,36]. Some studies show that low-density lipoprotein cholesterol, non-high-density
lipoprotein cholesterol (non-HDL-C) and the TC/HDL-C ratio are significant predictors of CVD [37,38].
The relationship between LDL-C/HDL-C lipid profiles is found to be a more useful indicator of CVD
risk than single, isolated lipid values [39]. In addition, some reports show that non-HDL-C is a better
indicator of the development of CVD than LDL-C [36]. Lipid profiles as the main indicator of stroke
prevention are still subject to significant uncertainty, in contrast to the clear results for CVD. However,
several studies attempted to assess the role of traditional and non-traditional lipid indices in predicting
stroke risk (Figure 1). Among the various non-traditional lipid variables, elevated baseline TC/HDL-C
ratio and TC/HDL-C ratio increases future vascular risk after stroke, but only elevated TC/HDL-C
ratio is associated with stroke recurrence risk [8]. Other studies estimated that the recurrence of
cerebral ischemia increases with age and the increased composition of non-traditional lipid variables
values: TC/HDL-C and LDL-C/HDL-C [40]. Zheng et al. showed that LDL-C, non-HDL-C and
LDL-C/HDL-C are associated with the future all stroke status, and TC, LDL-C, non-HDL-C, TC/HDL-C
and LDL-C/HDL-C are associated with the future ischemic stroke state [41]. Other studies show a
positive relationship between cholesterol levels and the risk of IS in men, while an inverse trend between
TC and the risk of hemorrhagic stroke is observed in the female group. A positive relationship was
found between TC/HDL-C ratio and risk of ischemic stroke in both sexes; however, these links are not
as clear after adjusting for body mass index, blood pressure and history of diabetes [17]. Other authors
also studied the impact of lipid profiles separately in men and women. TC/HDL-C ratio is mainly
associated with ischemic stroke and total stroke in men, while TG is more important in predicting
ischemic and total stroke in women. The authors of this study suggest that these two lipid indexes
have the most important prognostic value for identifying high risk participants predisposed to stroke
for each sex separately, and there may be potential goals for stroke prevention [42]. Some researchers
recommend that the level of non-traditional lipid profiles should be considered in the daily treatment
of ischemic stroke for the first prevention in clinical practice [8].
2.4. Number, Size and Composition of Lipoprotein Particle
Standard measurements of circulating lipids lack the ability to distinguish between the size,
density or concentration and composition of lipoproteins that may be important in assessing CVD
risk [43]. Therefore, in addition to the standard lipid components tested, several biomarkers of lipids
and lipoproteins are proposed as potential risk factors for the better detection of subclinical diseases [44].
Conventional HDL-C measures include the sum of cholesterol carried in HDL particles, but ignore
their composition, particle size, and subclass concentration. Additionally, TG may show divergent
relationships with vascular disease when transported in di↵erent lipoprotein molecules [9]. Above all,
the interest focuses on lipoprotein parameters such as the number and size of LDL and HDL particles,
and the number of intermediate-density lipoprotein (IDL) particles and lipoprotein(a) [Lp(a)]. One of
the most commonly used methods for measuring the size and concentration of lipoprotein particles
is nuclear magnetic resonance (NMR) spectroscopy. This technique simultaneously determines the
average size (in nanometers) and concentration (in mol/L) of lipoprotein particles [45]. Holmes
et al. assessed the relationship between metabolic markers and the risk of three cardiovascular
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diseases, including ischemic stroke. The study shows that the subclasses of lipoproteins and their
lipid components are associated with stroke risk. Cholesterol and triglycerides in apolipoprotein
B-containing lipoproteins (very low-density lipoprotein [VLDL], intermediate-density lipoprotein
[IDL] and low-density lipoproteins [LDL]) are positively associated with the risk of stroke. In contrast,
cholesterol in large and medium high-density lipoprotein particles inversely associates with the
ischemic stroke risk, while triglycerides in HDL particles positively associate with the risk of this
disease. VLDL particle concentrations are at least as strongly associated with ischemic stroke as
LDL particles. In addition, TGs are more consistently associated with IS across the entire lipoprotein
subfraction spectrum than cholesterol [9].
2.5. Elevated Lipoprotein(a) and the Risk of Ischemic Stroke
Lipoprotein(a) is an LDL particle with an added apolipoprotein(a). The link between Lp(a) and
stroke has been questioned by some researchers. Several studies show no association between Lp(a)
levels and the risk of stroke. Hachinski et al. did not notice a significant di↵erence in Lp(a) levels
among the patient and control groups [46]. Similarly, Glader et al. found no association between
baseline plasma Lp(a) values and future ischemic cerebral infarction [47]. In a prospective study in
Finland, no relationship was found between the initial Lp(a) plasma levels and the future risk of total
(all types of stroke) or thromboembolic stroke among those participating in the study [48]. More
recent meta-analyses summarize the existing evidence for Lp(a) and stroke from both control and
prospective studies and show a significant and independent association of elevated Lp(a) with an
increased risk of ischemic stroke [49–51]. The largest meta-analysis carried out by the Emerging Risk
Factor Collaboration analyzed the data from 13 prospective studies and confirmed that elevated Lp(a) is
an independent risk factor for ischemic stroke [49]. As many previously published reports investigating
the risk of stroke in patients with elevated Lp(a) levels did not show the underlying cause of the
stroke event; di↵erences in the etiology of stroke between cohorts may explain some of the inconsistent
results reported in the literature. Data suggest that Lp(a) primarily increases the risk of large-artery
atherosclerosis stroke [52]. According to the guidelines of the European Society of Atherosclerosis,
it is recommended to measure Lp(a) in patients with a medium or high risk of cardiovascular disease,
considering levels lower than 50 mg/dL [53]. Studies with larger cohorts are needed to see whether
higher cut-o↵ values than conventional and/or interactions with other risk factors are necessary to
establish the role of Lp(a) as a risk factor for ischemic stroke. Therefore, a more detailed study of the
relationship between individual subclasses of lipoprotein particles and lipid-associated characteristics
with the risk of CVD and stroke subtypes may be important and informative.
2.6. Polyunsaturated Fatty Acids and Risk of Ischemic Stroke
The n-3 polyunsaturated fatty acids (n-3 PUFAs) are a class of essential unsaturated fatty acids
necessary for proper biological activity and function in living organisms. The n-3 PUFAs are poorly
synthesized in the human body and have to be orally supplemented. Fish, such as mackerel, salmon,
tuna, sardines, herring, and halibut, are a major source of n-3 PUFAs in the human diet, and
they contain docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and eicosapentaenoic acid
(EPA) [54]. The n-3 PUFAs have potent anti-inflammatory activity, reduce platelet aggregation, stabilize
atherosclerotic plaques, and reduce major cardiovascular risk factors, including hypertension and
hyperlipidemia [55]. They can act as an antioxidant in reducing cerebral lipid peroxides and play
a role in regulating oxidative stress by increasing the oxidative burden and improving antioxidant
defense capabilities [56]. In addition, n-3 PUFAs trigger other responses, such as neurogenesis
and revascularization in stroke, which could be used in the development of acute-phase ischemic
stroke therapy [54]. Moreover, because ischemic stroke is a heterogeneous disorder with di↵erent
pathophysiological pathways and separate etiological subtypes, various mechanisms of PUFA action
should be considered. DHA plays a greater role in reducing the risk of atherothrombotic stroke by
reducing endothelial dysfunction and atherosclerosis [57], while EPA and DPA have a greater impact on
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the risk of cardioembolic stroke because of their e↵ect on clotting and atrial fibrillation [58]. The second
key component of a heart-healthy dietary pattern is a high content of n-6 PUFAs, obtained mainly from
vegetable oil, nuts, and seeds. Dietary n-6 PUFAs primarily include linoleic acid (LA) and arachidonic
acid (AA). The n-6 PUFAs have not generally been associated with stroke risk [59,60].
The Japan EPA Lipid Intervention Study (JELIS) has shown that treatment with highly purified
EPA and low-dose statins significantly reduces the incidence of coronary artery diseases and stroke
compared to statin therapy alone, without altering the reduction in low-density lipoprotein cholesterol
levels [61]. Nishizaki et al. reported that ratios of serum n-3 PUFAs to n-6 PUFAs, such as EPA/AA and
DHA/AA ratios, could be useful markers to determine the incidence of coronary events, peripheral
artery diseases, and early neurological deterioration after acute ischemic stroke [62]. Thies et al.
examined the e↵ect of fish oil administration on plaque regression and found that giving fish oil to
patients resulted not only in plaque regression but also an increases in EPA and DHA within the plaque
and a decrease in macrophage counts [63]. In addition, Ajami et al. reported that DHA+EPA provided
neuroprotection against ischemic brain injury by increasing the levels of antiapoptotic proteins, such
as Bcl-2 and Bcl-xL, thereby suppressing the inflammatory response [64].
Attention has also been focused on assessing the relationship between PUFA levels and early
neurological deterioration (END) in acute-phase ischemic stroke [65]. END occurs in approximately
one-third of patients in the acute phase of ischemic stroke and is associated with neurological and
functional decline. It also strongly correlates with poor functional outcome and usually leads to a
significant increase in mortality rate [66]. According to a recommended definition, END occurs when
there is an increase in the total National Institutes of Health Stroke Scale score of  2 points within 72 h
1–3 times a day after admission [67]. Suda et al. revealed that END is negatively associated with the
EPA/AA, DHA/AA, and EPA+DHA/AA ratios. The study shows that a low serum n-3 PUFA/n-6 PUFA
ratio might be an indication of possible END in patients with acute ischemic stroke, as demonstrated
in the population of Japanese stroke patients [65].
2.7. Fatty Acids and Cardioembolic Stroke
Elevated fatty acid (FA) levels are associated with several risk factors for atherosclerosis, including
abdominal obesity [68], arterial hypertension [69], and insulin resistance [70], as well as coronary
artery disease (CAD) [71], arrhythmia [72], and atrial fibrillation [73]. Because an association with
both atherosclerosis and arrhythmia has been reported, FAs may correlate with ischemic stroke.
However, the e↵ect of FAs on ischemic stroke is poorly understood. Because ischemic stroke is a
heterogeneous disorder with a variety of pathophysiological pathways, including atherothrombosis
and cardioembolism, the etiological subtypes of ischemic stroke should be analyzed separately [74].
Almost all long-term correlation studies of FAs and stroke risk estimate the level of FAs obtained with
food on the basis of self-reported questionnaires. Unfortunately, this is unclear for individual FAs
that are not well separated by dietary questionnaire data. For a more detailed assessment, Saber et al.
measured the levels of circulating n-3 PUFA phospholipids and examined their association with
ischemic stroke incidence, including atherosclerotic and cardioembolic stroke subtypes [75]. Patients
evaluated for phospholipid levels were recruited for three separate prospective cohort studies in the
US: the Cardiovascular Health Study (CHS), Nurses’ Health Study (NHS), and Health Professionals
Follow-Up Study (HPFS) [75]. The authors of these studies show that, among ischemic stroke subtypes,
DHA is inversely associated with atherothrombotic stroke and DPA is associated with cardioembolic
stroke. These relationships remain significant after including demographic, lifestyle, and vascular risk
factors. By comparison, EPA is not associated with total ischemic, atherothrombotic, or cardioembolic
stroke. The authors confirmed the hypothesis that individual FAs in serum have various associations
with ischemic, atherothrombotic, and cardioembolic stroke [75]. Earlier studies have shown that
elevated FA levels are associated with cardioembolic (CE) stroke, but this association was not seen
in non-CE stroke. Atrial fibrillation may potentially act as an intermediary between FAs and stroke
caused by cardioembolism [73]. Another study also found that an elevated FA concentration may
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serve as a marker of stroke caused by cardioembolism. In addition, the assessment of FA concentration
can predict the stroke recurrence following a CE stroke [76]. In patients with acute stroke, significantly
elevated FA levels are observed in groups with a higher risk of cardioembolism. These results suggest
that enhanced thrombogenicity may be the main mechanism explaining elevated FA levels in patients
with cardioembolic stroke [77].
2.8. The Role of Fish-Derived Fatty Acids in Stroke
For many years, intensive research has been carried out to assess the biological e↵ects of consuming
fish-derived PUFAs [78]. These studies confirm the view that n-3 PUFAs can a↵ect several cellular
processes known to be important in the development of cardiovascular disease, stroke, and protective
e↵ects [79,80]. Most studies have used doses of fish oils exceeding what is usually found in the
diet. Surprisingly, significant vascular benefits are observed even with modest fish consumption [81].
Long-term studies have shown that increased intake of n-3 PUFAs, in particular EPA and DHA,
can have a beneficial e↵ect on serum lipids [82], platelet aggregation [83], and bleeding time [84] and,
thus, may lead to a reduced risk of atherosclerosis and thrombotic complications [63]. Prolonged
fish consumption leads to increased incorporation of n-3 PUFAs into plasma lipids, erythrocytes, and
platelets [85]. After supplementation with fish oil, elevated EPA and DHA content in plasma lipids,
platelets, and erythrocyte membranes are observed with a simultaneous decrease in AA content [86].
In order to compare the e↵ects of n-3 PUFA consumption, the following four fish-derived sources of
n-3 PUFA were used: three rich sources (raw fatty fish [smoked salmon], cooked fatty fish [salmon
fillet], or fish oil [cod liver oil]) and one poor source (fish low in n-3 PUFA [cod fillet]). Therefore,
the following blood parameters were assessed: blood lipid composition and functional properties of
blood cells, as measured by the potential of lipopolysaccharide (LPS) to generate activation products
in whole blood [87]. Elvevoll et al. did not notice any significant di↵erences between the e↵ects of
eating cooked fish compared to raw fish (smoked salmon). They found that the intake of fatty fish
is more e↵ective in increasing EPA and DHA than supplementing with fish oil and is more likely
to have a beneficial e↵ects on HDL cholesterol and whole blood activation reactions [87]. However,
another group of researchers showed that the action of DHA-rich oil (without EPA) had a comparable
hypotriglyceridemic e↵ect as a fish diet and fish oil supplementation. Moreover, a fish diet and fish oil
supplementation increased the proportion of n-3 PUFA in plasma lipids, platelets, and erythrocyte
membranes [88].
2.9. Lipid-Lowering Therapy for Prevention of Ischemic Stroke
Over the past two decades, compelling evidence from clinical trials revealed the importance
of low-density lipoprotein cholesterol-lowering therapies in reducing cardiovascular and stroke
morbidity and mortality [89,90]. At present, there is a more than four-fold increase in the use of
cholesterol-lowering agents in our population compared to in 2000. There is strong evidence for the
role of statins in stroke prevention and association with an approximately their 20% risk reduction [91],
in particular a decreased risk of ischemic stroke [92]. Moreover, more aggressive statin treatment
improves the long-term functional outcome of patients discharged after an acute ischemic stroke
more than less aggressive treatment [93]. One of the most commonly used statins to lower high
cholesterol is atorvastatin. It is a common statin used to investigate the e cacy of statin therapy,
especially high-intensity statin therapy in patients with ischemic stroke. Preliminary studies have
shown that in patients with recent stroke or transient ischemic attack and without coronary heart
disease, 80 mg atorvastatin daily reduces the overall incidence of stroke and cardiovascular events,
despite a slight increase in the incidence of hemorrhagic stroke [94]. Many studies have confirmed the
e↵ect of atorvastatin at lowering lipids and decreasing the number and frequency of vascular incidents,
as well as its clinical e cacy at reducing the burden of disease after stroke or transient ischemic
attack [95,96]. Atorvastatin improves endothelial function, enhances the stability of atherosclerotic
plaque, and inhibits inflammatory and thrombogenic responses in arterial walls [97]. In the latest
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Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCLs) cohort trial, atorvastatin
was compared with a placebo in patients with recent stroke or transient ischemic attack. Atorvastatin
was found to reduce the first occurrence of stroke and the first occurrence of composite vascular
events [98].
During recent years, new drug classes proved their e cacy and safety in lowering cholesterol and
preventing cardiovascular incidents in randomized controlled studies. PCSK9 (proprotein convertase
subtilisin/kexin type 9) inhibitors increase the number of available LDL receptors on the surface of
hepatocytes, which leads to a higher cleavage of LDL-C from the circulation. The mechanism of action
of PCSK9 inhibitors involves halting the metabolic breakdown of LDL-R, resulting in increased LDL-C
clearance. The two currently available antibodies (Alirocumab and Evolocumab) against PCSK9 are
fully human IgG subtypes that bind with an approximate 1:1 stoichiometry to circulating PCSK9 and
prohibit its binding to the LDL-R. The mean percentage change in LDL-C levels decreases by 50% or
more from baseline in patients receiving PCSK9 inhibitors [99]. Several non-antibody therapies have
also been developed to inhibit PCSK9 function. Gene silencing or editing technologies were used,
such as antisense oligonucleotides [100], small interfering RNAs [101], small-molecule inhibitors [102],
mimetic peptides [103], adnectins [104], and vaccinations [105].
According to the American Heart Association and American Stroke Association guidelines for
stroke prevention, which recognize triglyceride as a risk factor for stroke, fibric acid derivatives can
be considered in patients with hypertriglyceridemia [106]. Fibric acid derivatives (e.g., gemfibrozil,
fenofibrate, and bezafibrate) lower triglyceride levels and increase HDL cholesterol. The Veterans
Administration HDL Intervention Trial of men with low HDL-C and associated coronary artery disease
showed that gemfibrozil reduces the risk of all strokes, mainly ischemic strokes [107].
The issue of elevated Lp(a) level therapy is slightly di↵erent. Lp(a) levels are essentially
unresponsive to traditional lipid-lowering drugs such as statins or fibrates. Some lipid-lowering
agents that are not specific for Lp(a) reduce Lp(a) levels (e.g., niacin, PCSK9 inhibitors, and CETP
inhibitors) [108]; however, to date, no randomized controlled trial has demonstrated that the lowering
of Lp(a) leads to decreased risk of cardiovascular disease. Recent findings show that antisense
oligonucleotides can be used to inactivate genes involved in the pathogenesis of vascular diseases.
To lower Lp(a), synthetic oligonucleotides have been developed. In clinical trials, Mipomersen
(Genzyme/ISIS Pharmaceuticals), an antisense oligonucleotide targeted to apolipoprotein B, reduced
Lp(a) by 21% to 39% [109]. AKCEA-APO(a)-LRx (Akcea Therapeutics/Ionis Pharmaceuticals) is the
latest antisense oligonucleotide targeted to apolipoprotein(a). In a phase II trial, the specific antisense
oligonucleotide resulted in a dose-dependent reduction of 66% to 92% in blood circulating Lp(a) and is
expected to enter into a phase III study in 2020.
3. Lipids of the Brain during Ischemic Stroke
The brain has the second highest lipid content among the organs of the human body, accounting
for about 50% of its dry weight [110]. Lipids that are essential for the central nervous system are
classified into five major subcategories: fatty acids, triglycerides, phospholipids, sterol lipids, and
sphingolipids. They serve as the structural components of biological membranes, act as messengers
in cellular signaling pathways and contribute to the energy supply [111]. For example, about 20%
of the brain total energy requirements comes from the oxidation of fatty acids, which takes place in
astrocytes [112].
Brain tissue is characterized by cellular heterogeneity; thus, the fatty acid composition varies
between di↵erent cell types. In the ischemic brain, the levels of di↵erent lipids change compared
to the control conditions [113]. It is even possible to distinguish the ischemic core area from the
penumbra according to the post-stroke lipid profiles [114]. Generally, brain tissue is characterized
by a high proportion of polyunsaturated fatty acids: arachidonic acid (AA; omega-6; C20:4!6),
eicosapentaenoic acid (EPA; omega-3; C20:5!3), and docosahexaenoic acid (DHA; omega-3; C22:6!3).
Arachidonic acid and docosahexaenoic acid make up ⇠20% of fatty acids in the mammalian brain [115].
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All of these lipids are located in cellular membranes and are essential for the normal structure and
function of the central nervous system [110]. However, cerebral ischemia initiates a cascade of events
that stimulates the release of free fatty acids from the membrane. In particular, there is a rapid
accumulation of arachidonic acid, docosahexaenoic acid, diacylglycerol, and platelet-activating factor
(PAF; 1-Oalkyl-2-acyl-sn-3-phosphocholine).
The released arachidonic acid is highly reactive and prone to downstream enzymatic
reactions that generate di↵erent classes of eicosanoids in the brain area a↵ected by the ischemia
(Figure 2). These molecules play a major role in cerebral vasoconstriction, edema, neurotoxicity and
neuroprotection that occur after ischemia and reperfusion in the brain following stroke episodes. The
cytosolic phospholipase A2 alpha (cPLA2↵), an enzyme responsible for arachidonic acid release from
membrane phospholipids, plays a key role in post-ischemic brain pathology. The down-regulation of
cytosolic phospholipase A2 alpha expression [116] or blockage of its activity with specific antibodies [117]
attenuates ischemic brain damage in the mouse model of cerebral ischemia-reperfusion injury.
Figure 2. Eicosanoid biosynthesis pathways. Enzymes involved in biosynthetic pathways are denoted
as: cPLA2, cytosolic phospholipase A2; COX-1, cyclooxygenase 1; COX-2, cyclooxygenase 2; PGIS,
prostaglandin-I synthase; TBXAS-1, thromboxane-A synthase; PGES-1, prostaglandin E synthase;
12/15-LOX, 12/15-lipoxygenase; 5-LOX, 5-lipoxygenase; CYP4A, cytochrome P450 4A subfamily; CYP4F,
cytochrome P450 4F subfamily; CYP2C, cytochrome P450 2C subfamily; CYP2J, cytochrome P450 2J
subfamily; sEH, soluble epoxide hydrolase. Lipid molecules generated in biosynthesis are denoted as:
AA, arachidonic acid; PGH2, prostaglandin H2; PGI2, prostaglandin I2, prostacyclin; TXA2, thromboxane
A2; PGE2, prostaglandin E2; LTs, leukotrienes; 5-HETE, 5-hydroxyeicosatetraenoic acid; LXs, lipoxins;
12-HETE, 12-hydroxyeicosatetraenoic acid; 15-HETE, 15-hydroxyeicosatetraenoic acid; 20-HETE,
20-hydroxyeicosatetraenoic acid; 5,6-EET, 5,6-epoxyeicosatrienoic acid; 8,9-EET, 8,9-epoxyeicosatrienoic
acid; 11,12-EET, 11,12-epoxyeicosatrienoic acid; 14,15-EET, 14,15-epoxyeicosatrienoic acid; DHETs,
dihydroxyeicosatrienoic acids. Thumb symbol denotes beneficial or detrimental e↵ects on the
post-stroke brain of eicosanoids discussed in this review.
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The DHA released during the ischemic event is converted enzymatically into lipid messengers. One
of them is the neuroprotectin D1 (NPD1), a potent cell-protective, pro-survival and anti-inflammatory
lipid mediator in experimental stroke models [118,119]. This experimental post-stroke DHA treatment
improves the neurobehavioral recovery and reduces brain infarct volume. This research shows that
the additional DHA enhances the synthesis of NPD1 in the penumbra, revealing a highly desirable
neuroprotective e↵ect [118].
The excessive accumulation of platelet-activating factor in the ischemic brain contributes to
excitotoxicity, Ca2+ uptake, and mitochondrial dysfunction, leading to neuronal death. However, the
disruption or inhibition of PAF-receptor has a neuroprotective e↵ect [120,121].
4. Eicosanoids in Ischemic Stroke
Eicosanoids belong to oxylipins, a family of oxidized forms of polyunsaturated fatty acids.
They are produced by enzymatic reactions catalyzed by three di↵erent enzymes—cyclooxygenases,
lipoxygenases and cytochrome P450 monooxygenases. This diverse group of compounds
includes prostanoids (i.e., prostaglandins, prostacyclin, and thromboxanes), leukotrienes, lipoxins,
hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatrienoic acids (EETs), resolvins, and eoxins.
In general, eicosanoids are biologically active compounds involved in the regulation of many
physiological functions, but they are also related to pathological processes, including ischemic stroke.
4.1. Biosynthesis and Physiological Role of Eicosanoids
Eicosanoids are synthesized from arachidonic acid, a precursor, 20-carbon polyunsaturated fatty
acid released from cell membranes by phospholipase A2 (PLA2). Free arachidonic acid, as a highly
reactive compound is prone to further oxidation and is readily converted into eicosanoids in their
downstream enzymatic pathways (Figure 2). Cyclooxygenases (COX-1 and COX-2) convert the free
arachidonic acid into the unstable prostaglandin H2 (PGH2), which is next converted by downstream
prostanoid synthases into prostaglandins D2, E2, F2, and I2 (PGD2, PGE2, PGF2 and PGI2, respectively)
or thromboxane A2 (TXA2) [122]. Arachidonic acid is also converted by lipoxygenases (LOX enzymes)
to produce leukotrienes, lipoxins and HETEs, while cytochrome P450 converts the arachidonic acid
into 20-HETE and EETs molecules.
Eicosanoids are known for their various and often contradictory roles in the human body. On the
one hand, they regulate many physiological functions in the cardiovascular, gastrointestinal, urogenital,
and nervous system. They play critical roles in immunity, acting as pro- and anti-inflammatory
agents, regulating fever, and triggering platelet aggregation, blood clotting, muscle contraction,
vasoconstriction, and vasodilation. On the other hand, eicosanoids play an important role in
cardiovascular diseases and stroke, renal diseases, rheumatoid arthritis, Alzheimer’s disease, cancer,
and even infectious diseases [123,124].
4.2. The Role of Eicosanoids in Ischemic Stroke Pathology
The role of eicosanoids in stroke is reported to be both beneficial and detrimental. The levels
of many eicosanoids are altered following the ischemic insult and often stay elevated during the
recovery phase, thus playing an important role in either brain tissue injury or protection. The balance
between neuroprotection and neuronal cell death caused by the post-stroke disruption of eicosanoid
homeostasis is detrimental for the size of the disease pathology and the extent of stroke patient recovery.
In the following sections, principal findings of the current investigations on the role of di↵erent classes
of eicosanoids in ischemic stroke pathology as well as possible targets for therapeutic interventions
will be reviewed.
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4.2.1. Prostanoids in Ischemic Stroke
Prostanoids group arachidonic-acid derivatives which are generated by cyclooxygenase enzymes.
These include prostaglandins PGE2, PGD2, PGF2↵, PGI2, and thromboxane A2 (Figure 2). Two distinct
isoforms of cyclooxygenase are involved in the prostanoid biosynthetic process: COX-1, which is found
in the kidney, stomach and platelets, and COX-2, located in macrophages, leukocytes and fibroblasts.
In the central nervous system, COX-1 is constitutively expressed in neurons, astrocytes, and microglial
cells, while COX-2 is up-regulated under pathological conditions [125].
Special interest in the pathogenesis of ischemic stroke concerns the role of two prostanoids:
prostacyclin, also known as prostaglandin I2 (PGI2), and thromboxane A2 (TXA2). Prostacyclin is
a potent vasodilator and inhibitor of platelet aggregation. In contrast, thromboxane A2 is a strong
vasoconstrictor and inductor of platelet aggregation [126]. The over-production of TXA2 is one of
the key factors causing thrombosis, stroke, and heart disease. PGI2 is the primary arachidonic acid
metabolite in vascular walls; due to its contrasting biological activity to TXA2, PGI2 represents the
most potent endogenous vascular protector, acting as an inhibitor of platelet aggregation and a strong
vasodilator on vascular beds [127]. PGI2 acts mostly as an immune-inhibitory molecule through
multiple cell types such as dendritic cells, macrophages, and T-cells. The decreased biosynthesis
of anti-thrombotic PGI2 alongside with the excessive production of pro-inflammatory PGE2 and
pro-thrombotic TXA2 increases the risk of stroke and heart attack in gene-knockout models [128].
Another study using the transgenic mouse model revealed that the redirection of arachidonic acid
conversion toward favoring PGI2 production over TXA2 and PGE2 clearly contributes to resistance
to induced ischemic stroke [128]. This experimental attempt uses genetic engineering to link the
COX-1 enzyme, which generates the unstable prostaglandin H2 (PGH2) from arachidonic acid, with the
PGIS enzyme that generates PGI2 from PGH2 intermediates. Since PGH2 serves as a substrate for
the production of all of the downstream prostanoids (including PGI2, PGE2) and thromboxane A2,
this approach enables the regulation of prostanoid biosynthesis in favor of PGI2 rather than TXA2 and
PGE2 in cells by channeling the PGH2 intermediate to the PGIS biosynthetic pathway [128].
The post-stroke accumulation of PGE2 is also accompanied by a marked induction of the prostanoid
EP2 receptor expression in the ischemic hemisphere, particularly in neurons of the penumbra [129].
The EP2 signaling pathway contributes to ischemic injury but its inhibition e ciently protects against
the inflammatory neurodegeneration observed in post-ischemic brain tissue. In addition, the other
EP1 prostanoid receptor is also up-regulated following ischemic stroke and its expression is not only
detected in neurons but also in the endothelial cells [130]. The PGE2 action, mediated by the EP1
receptor, leads to the disruption of the blood–brain barrier which, in turn, significantly contributes to
progressive neuronal death in the stroke penumbral region. Additionally, in this case, inhibition of the
EP1 receptor reduces the infarct volume, blood–brain barrier disruption and permeability, neutrophil
infiltration and hemorrhagic transformation in the animal stroke model.
4.2.2. Leukotrienes in Ischemic Stroke
Leukotrienes (LTs) are synthesized form arachidonic acid by the 5-lipoxygenase (5-LOX) enzyme;
this process also requires the presence of 5-LOX-activating protein (FLAP). The pathway generates
two groups of leukotrienes: dihydroxy acid leukotriene B4 (LTB4) and cysteinyl-leukotrienes (i.e.,
LTC4, LTD4, and LTE4) (Figure 2). Leukotrienes are thought to be involved in atherosclerosis and
plaque formation, a process leading to cardio- and cerebrovascular pathology that eventually leads
to occlusion resulting in stroke. However, as leukotriene levels increase after ischemia, they are also
considered the factors responsible for the post-stroke pathology.
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Numerous studies pinpoint leukotriene B4 (LTB4) as the factor responsible for pathological events
occurring during the post-ischemic state. Both the expression of 5-lipoxygenase and the levels of
leukotrienes increase following focal cerebral ischemia in rats and persist for days after reperfusion
in the ischemic core and the boundary zones [131]. The increased and sustained plasma level of
leukotriene B4 is associated with the poor functional recovery of patients with acute middle cerebral
artery infarction [132]. However, studies using animal or cell culture models consistently show that the
regulation of 5-lipoxygenase expression results in a neuroprotective e↵ect in cases of ischemia [133–135].
An evident post-ischemic brain injury is also mediated by the cysteinyl-leukotrienes but is associated
with neuronal damage and astrogliosis [136].
4.2.3. Lipoxin A4 in Ischemic Stroke
Lipoxins (LXs) are a class of eicosanoids that exert anti-inflammatory and pro-resolving activities,
generally reducing tissue injury and chronic inflammation. The synthesis of LXs from arachidonic acid
involves three major lipoxygenases: 5-LOX, 15-LOX, and 12-LOX (Figure 2). Additionally, LXs may be
synthesized in an aspirin-triggered pathway [137].
One representative of this group of molecules, lipoxin A4 (LXA4), has been shown to be very
e↵ective in neuroprotection after brain ischemia-reperfusion injury. The experimental treatment
with LXA4 e↵ectively reduces infarct volume and brain edema, improving the neurological outcome,
as shown for rats after middle cerebral artery occlusion [138,139]. The authors of the studies suggest that
the e↵ect obtained with the treatment may be generated by the inhibition of 5-lipoxygenase translocation
triggered by LXA4 and the resulting reduced biosynthesis of pro-inflammatory leukotrienes [138].
The protective e↵ect of lipoxin A4 also applies to astrocytes. The treatment of these cells with
LXA4 protects against cell damage and attenuates the production of reactive oxygen species under
oxygen-glucose deprivation and re-oxygenation conditions [140]. Up-regulation of the nuclear factor
erythroid 2-related factor 2 (Nrf2) signaling pathway links lipoxin A4 with reduction of oxidative stress
that most likely underlies its protective e↵ect.
4.2.4. Hydroxyeicosatetraenoic Acids in Ischemic Stroke
Hydroxyeicosatetraenoic acids (HETEs) are formed from arachidonic acid in three di↵erent
metabolic pathways [141]. The predominant pathway involves lipoxygenases (5-LOX, 12-LOX, and
15-LOX enzymes) that form a variety of HETE molecules, including 5-HETE, 12-HETE, and 15-HETE
(Figure 2). Small amounts of 11-HETE and 15-HETE can be generated by the cyclooxygenases
COX-1 and COX-2. Some HETEs, with the 20-HETE molecule at the forefront, are generated by
cytochrome P450 hydroxylases. The analysis of HETEs composition and quantity in rat brains exposed
to ischemia reveals that the amount of HETE molecules tends to increase with time following the
occlusion [142]. After 72 h, almost all lipoxygenase-generated HETEs are significantly increased in the
a↵ected brain tissue.
Animal studies show that hypoxia up-regulates the expression of 15-lipoxygenase in the brain
artery endothelium after stroke and leads to the increased production of 15-HETE [143]. 15-HETE
promotes angiogenesis and neuronal recovery that protects against ischemic brain infarction and
improves neurological function in a mouse model of focal ischemia. It also stimulates the proliferation
and migration of brain microvascular endothelial cells with the PI3K/Akt signaling pathway involved.
Another study shows that 15-HETE boosts the angiogenesis in mouse ischemic brain by up-regulation
of the vascular endothelial growth factor (VEGF) [144].
Contradictory results are obtained on the role of the 20-hydroxyeicosatetraenoic acid (20-HETE)
in stroke pathology as it is either described as detrimental or beneficial. 20-HETE is produced
by cytochrome P450 members, mainly CYP4A and CYP4F. The role of 20-HETE in ischemic brain
pathology depends on whether it is determined in the early or late post-stroke phase. On the one hand,
elevated 20-HETE levels that are detected in the plasma of ischemic stroke patients associate with
greater lesion size and neurological impairment, reduced cognitive functions and poorer functional
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independence in daily living [145]. Some authors propose that this particular eicosanoid may serve as
a valuable predictor of neurological deterioration prognosis in acute minor ischemic stroke as their
findings indicate the association of high 20-HETE plasma levels and neurological deterioration and
poorer prognosis in patients [146]. The increased production of 20-HETE is also observed in animal
ischemia-reperfusion models [147,148]. For example, the expression of 20-HETE synthase increases
in the plasma and brain of animals after experimental cerebral ischemia and clearly contributes to
oxidative stress and endothelial dysfunction [148].
On the other hand, the increase in CYP4A expression and 20-HETE production following
oxygen-glucose deprivation noted in astrocytes promotes angiogenesis via the induction of endothelial
cell proliferation, tube formation and migration in a later stage of stroke [149]. The specific
cross-talk discovered between astrocytes and endothelial cells is mediated by 20-HETE and involves
HIF-1↵/VEGF and JNK signaling pathways. The beneficial e↵ects of 20-HETE on recovery from
stroke are confirmed—the inhibition of CYP4A, an enzyme involved in 20-HETE synthesis, resulted in
diminished peri-infarct angiogenesis and worsened neurological deficits in mice. The authors highlight
that, although 20-HETE induces neuronal and vascular injury in the early post-stroke phase, in the
later post-stroke phase, this mediator is necessary for neurovascular repair and remodeling to obtain
functional recovery after stroke.
4.2.5. Epoxyeicosatrienoic Acids in Ischemic Stroke
The synthesis of epoxyeicosatrienoic acids (EETs) from arachidonic acid is catalyzed by cytochrome
P450 epoxygenases from the CYP2C and CYP2J families. Four biologically active EETs belong to
this group of eicosanoids: 5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET (Figure 2). These molecules
are metabolized to less bioactive dihydroxyeicosatrienoic acids (DHETs) by the soluble epoxide
hydrolase (sEH).
EETs exert strong neuroprotective e↵ects in the case of cerebral ischemia, especially with
regard to components of the neurovascular unit. While oxygen-glucose deprivation decreases
the viability of cerebral smooth muscle cells, di↵erent types of EETs prevent these events during in vitro
experiments [150]. 14,15-EET shows the strongest anti-apoptotic e↵ect under these conditions [150,151].
Two pathways are linked to the protective e↵ects of EETs: PI3K/Akt pathway and ATP-sensitive
potassium channels contribute to the EETs-protective e↵ects on cerebral microvascular smooth muscle
cells [151], while the JNK/c-Jun and mTOR signaling pathway contributes to the anti-apoptotic e↵ect
of 14,15-EET under conditions of oxygen-glucose deprivation [150].
4.3. Eicosanoids as the Target for Ischemic Stroke Treatment
The emphasis on the role of eicosanoids in the pathology of ischemic stroke has opened up
new perspectives for the development of treatments based on modifications within the biosynthetic
pathways of these lipid mediators.
The modulation of prostanoid biosynthesis with cyclooxygenase inhibitors has been proposed as
one potential treatment strategy. To date, aspirin is the only antiplatelet agent that is used e↵ectively in
the early treatment of acute ischemic stroke. Aspirin irreversibly inhibits COX activity in platelets
and prevents the conversion of AA to thromboxane A2. The decline in the risk of mortality and
morbidity when aspirin is initiated within 48 h of acute ischemic stroke is small though significant [152].
Targeting prostanoid biosynthesis with COX-2 inhibitors, such as nonsteroidal anti-inflammatory
drugs (NSAIDs), the classical pain medications, or the novel COX-2 selective inhibitors (e.g., celecoxib
or rofecoxib), has been shown to reduce edema, neuroinflammation, and infarct size in rodent stroke
models [153]. Although administration of these drugs reveals a neuroprotective e↵ect in stroke models,
adverse e↵ects, including an increased risk of stroke, occur following long-term usage. A recent increase
in the number of heart attacks related the use of COX-2 inhibitors is attributed to their ability to reduce
PGI2 and increase TXA2 biosynthesis in vascular walls and platelets [154]. A disrupted production
balance in favor of TXA2 over PGI2, the most important vascular protector, is shown to be responsible,
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at least in part, for the pro-thrombotic and pro-atherogenic e↵ects [155]. A clinical trial of a small
group of ischemic stroke patients confirmed that treatment with intravenous prostacyclin infusions
results in clinical improvement, with regression of hemiplegia or hemiparesis, the disappearance of
aphasia, and clearing of consciousness within a few hours after administration [156]. Vasodilation of
cerebral microvessels is the e↵ect that may account for the benefit of PGI2 on post-ischemic brain tissue.
Interestingly, statins, apart from their lipid-lowering activity, have also been shown to be e↵ective in
reducing TXA2 levels in ischemic stroke patients [157]; thus, extensive studies should investigate the
role of statin use as a post-stroke treatment.
The lowering of leukotriene B4 synthesis as an ischemic stroke treatment has also been
intensively investigated. For example, the experimental inhibition of 5-lipoxygenase with zileuton,
an anti-asthmatic drug, attenuates inflammation in the ischemic zone, reduces brain damage, neuronal
apoptosis, infarct volume and even improves neurological deficits [133–135]. Similar neuroprotection
against the injury caused by ischemia-reperfusion is also mediated by the regulation of 5-lipoxygenase
expression by microRNA [158]. The disruption or inhibition of the FLAP to block leukotriene synthesis is
as e cient in reducing brain edema and neuroinflammation [159]. Antagonists of cysteinyl-leukotriene
receptor 1, pranlukast [136], or receptor 2, HAMI 3379 [160], protect against cerebral ischemic injury,
ameliorate neuron loss, inhibit astrocyte proliferation, decrease cytokines release, microglial activation
and neutrophil accumulation in ischemic regions.
The level of 20-HETE can be e↵ectively modulated by selective inhibitors, such as TS-011 or
HET0016, or by the 20-HETE antagonist, 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid. Administration
of these agents results in reduced infarct volume, improved microcirculation in the infarct area, and
better post-ischemic neurological outcomes in animal stroke models [147,161–163]. However, as the
role of 20-HETE is reported to be both detrimental and beneficial for stroke pathology, the appropriate
modulation of the level of this eicosanoid may be challenging in diverse post-stroke stages.
Increasing lipoxin A4 levels seem to be a promising treatment approach; however, physiologically,
LXA4 is rapidly inactivated. Thus, synthetic analogues could be more promising agents for that kind
of stroke therapy. For example, the BML-111 analog of LXA4 reduces the infarct volume and improves
sensorimotor function in the early post-ischemic phase in rats, but does not a↵ect behavioral deficits in
the long-term [164]. However, the administration of an LXA4 analog was e cient in reducing levels of
pro-inflammatory cytokines and chemokines and increasing the anti-inflammatory cell populations
in the post-ischemic brain. Another lipoxin A4 analog, LXA4 methyl ester (LXA4ME), was shown to
reduce the brain injury by ameliorating the blood–brain barrier dysfunction in a rat model of transient
or permanent cerebral ischemic injury [165].
Reduction of the infarct volume, apoptosis in the ischemic area and the amelioration of neurological
deficits can also be achieved by blocking of the downstream EET metabolism by inhibitors of
sEH [166–168]. Both cell culture and animal studies prove that sEH inhibitors mediate cerebral
protection by increasing the levels of EETs. For example, astrocytes treated with sEH inhibitors
increase the concentration of EETs after the ischemia-like event and, as a result, release higher levels of
protective neurotrophic factors, such as vascular endothelial growth factor (VEGF), which prevent
neuronal cell death [167]. Another study showed that 14,15-EET itself or the inhibition of sEH
attenuates neuronal apoptosis, astrogliosis and microglia activation, reduces inflammatory responses
and promotes angiogenesis in the rat brain after occlusion of the middle cerebral artery [169].
5. Conclusions
Stroke is a devastating brain injury with tremendous consequences for human health.
Understanding the pathophysiology of ischemic stroke is critical for reducing the burden of the
disease or developing therapies. Lipids and lipid mediators, such as eicosanoids, largely contribute to
the pathophysiology of ischemic stroke and possible mechanisms of their involvement, discussed in
this review, are summarized on Figure 3.
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The prevalence of stroke continuously increases because the elderly population is growing faster
than the populations of other ages. Stroke is one of the main causes leading to disability and reduced
quality of life worldwide; thus, the development of preventive and therapeutic interventions is
urgently needed. Approved treatments for ischemic stroke are limited to aspirin, recombinant tissue
plasminogen activator (rtPA) and mechanical thrombectomy. Each year, we observe the progress in
stroke research, but the findings are not always successfully translated into the clinic.
Figure 3. Possible mechanisms of involvement of serum lipids and eicosanoids in the pathophysiology
of ischemic stroke. Arrows indicate stimulation, while bar-headed lines indicate inhibition. Green
color stands for beneficial, while red for detrimental e↵ects. Abbreviations used: 15-HETE,
15-hydroxyeicosatetraenoic acid; 20-HETE, 20-hydroxyeicosatetraenoic acid; EETs, epoxyeicosatrienoic
acids; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); PGE2,
prostaglandin E2; PGI2, prostaglandin I2, prostacyclin; PUFAs, polyunsaturated fatty acids; TXA2,
thromboxane A2.
An e↵ective stroke treatment must focus on rescue of the penumbra zone from ischemic injury
to preserve the viability and vitality of as many cells in this zone as possible. Studies on cell
culture and animal stroke models have indicated many potential targets for therapeutic interventions
within the biosynthetic pathways of lipids and lipid mediators, especially eicosanoids, derived from
polyunsaturated fatty acids (summarized in Table 1). Specific enzyme inhibitors, expression modulators
or receptor antagonists are able to redirect the metabolite flow in a way that beneficial rather than
detrimental e↵ects in the post-stoke brain tissue can be obtained. Neuroprotective, anti-inflammatory
and pro-angiogenic e↵ects of these experimental treatments attenuate ischemic brain damage, reduce
the infarct area, boost the microcirculation and improve neurological deficits and recovery; however,
a lot of research is necessary to determine the molecular mechanisms, e cacy and safety of that kind
of intervention.
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A number of serum lipids are associated with the risk of ischemic stroke. In clinical practice,
the most common laboratory tests determine only the traditional lipid profile. However, research
findings show that, for example, lipid ratios are better predictors of vascular risk than a single
isolated lipid value. Conventional serum lipid measurements often ignore additional parameters like
composition, particle size or the concentration of lipid subclass. Studies show that non-traditional
lipids may also be good predictors of stroke risk. More evidence is needed to fully unravel the
relationship between lipids, type of lipids, lipid profile (traditional and non-traditional) and stroke.
However, it is worth considering including non-traditional lipid measures in daily clinical practice to
better predict the risk of stroke in a patient or monitor the recovery of a patient who had already had a
stroke episode.
Table 1. Therapeutic interventions targeting lipids and lipid mediators in the prevention and treatment
of ischemic stroke.
Therapeutic Intervention 1 E↵ect Application 2 Reference
Lipid-lowering therapies for stroke prevention
Lowering cholesterol with statins Anti-atherogenic: LDL cholesterol decrease Clinical use [91,92,97]
Lowering cholesterol with PCSK9 inhibitors,
siRNAs, mimetic peptides, adnectins,
vaccinations
Anti-atherogenic: increased LDL-C clearance
from circulation Experimental [99–105]
Reduction of hypertriglyceridemia with fibric
acid and derivatives
Anti-atherogenic: triglyceride decrease; HDL
cholesterol increase Clinical use [106,107]
Lowering Lp(a) levels with niacin, PCSK9 or
CETP inhibitors, or antisense oligonucleotides Anti-atherogenic: reduced Lp(a) in circulation Experimental [108,109]
Eicosanoid-targeted therapies for post-ischemic brain tissue rescue
Lowering prostaglandins level with
COX inhibitors
Anti-atherogenic: anti-platelet e↵ect of aspirin
Neuroprotection: anti-inflammatory actions Clinical use Experimental [152,153,170]
Increasing prostacyclin levels with
intravenous infusions Vasodilation of cerebral microvessels Experimental [156]
Lowering TXA2 levels with statins
Anti-thrombogenic: TXA2 level decrease,
anti-platelet activity Experimental [157]
Decreasing leukotriene B4 synthesis with 5-LOX
inhibitors, microRNAs, FLAP inhibitors, or
CysLT receptors antagonists
Neuroprotection: anti-inflammatory and
anti-apoptotic actions, reduced neuronal loss Experimental [133–136,158–160]
Increasing lipoxin A4 levels with LXA4 or
LXA4ME analogues
Neuroprotection: anti-inflammatory action,
blood–brain barrier rescue Experimental [164,165]
Lowering 20-HETE levels with inhibitors
or antagonists Neuroprotection: improved microcirculation Experimental [147,161–163]





1 Abbreviations: 20-HETE, 20-hydroxyeicosatetraenoic acid; 5-LOX, 5-lipoxygenase; CETP, cholesterylester transfer
protein; COX, cyclooxygenase; CysLT, cysteinyl leukotriene; EETs, epoxyeicosatrienoic acids; FLAP, 5-LOX-activating
protein; Lp(a), lipoprotein(a); LXA4, lipoxin A4; LXA4ME, lipoxin A4 methyl ester; PCSK9, proprotein convertase
subtilisin/kexin type-9; sEH, soluble epoxide hydrolase; TXA2, thromboxane A2. 2 Clinical use: therapeutic
interventions used as a standard prevention or treatment for stroke patients. Experimental: therapeutic interventions
tested in preclinical or clinical studies, but currently not translated into the clinic.
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Abbreviations
AA arachidonic acid
CAD coronary artery disease
CE cardioembolic
CETP cholesterylester transfer protein
COX cyclooxygenase
























LXA4ME lipoxin A4 methyl ester
NMR nuclear magnetic resonance




PCSK9 proprotein convertase subtilisin/kexin type-9
PG prostaglandin
PGE2 prostaglandin E2
PGI2 prostaglandin I2, prostacyclin
PUFA polyunsaturated fatty acid




VEGF vascular endothelial growth factor
VLDL very low-density lipoprotein
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